Company intelligence / Profile preview

D3solutions

Ownership: Private
Development stage: Other

Overview

D3 Bio has built a pipeline of multiple pre-clinical stage oncology programs with first-in-class or best-in-class potential. These target immune pathways or tumor-driving mutations. The company owns global rights to all its programs and aims to address major unmet needs in cancer treatment by developing biomarker-driven precision medicines. Clinical data have not yet been published, but early presentations at international symposia highlight innovation in their approach[1][2].

Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on D3solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D3solutions.

Explore the full profile